Lung cancer (non-small cell)
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Who can joinAdults
Age18+ years
Kind of studyPhase 3: compared with usual treatment
What it testsA medicine
The full list of who can and cannot join is on the registry. Ask the trial team, or write to us and we will explain it in simple words.
Where to go
13 hospitals in India taking patients for this trial.
Apollo Hospitals - Visakhapatnam - Health CityVisakhapatnam, Andhra PradeshDirections ↗
Hemato Oncology ClinicAhmedabad, GujaratDirections ↗
Marengo CIMS HospitalAhmedabad, GujaratDirections ↗
All India Institute of Medical SciencesNew Delhi, National Capital Territory of DelhiDirections ↗
Vardhman Mahavir Medical College and Safdarjung HospitalNew Delhi, National Capital Territory of DelhiDirections ↗
Rajiv Gandhi Cancer Institute And Research CentreNew Delhi, National Capital Territory of DelhiDirections ↗
Institute of Medical Sciences and Sum HospitalBhubaneswar, OdishaDirections ↗
Meenakshi Mission Hospital and Research CentreMadurai, Tamil NaduDirections ↗
Yashoda Hospitals - Hitech CityHyderabad, TelanganaDirections ↗
Mahamana Pandit Madan Mohan Malviya Cancer CentreVaranasi, Uttar PradeshDirections ↗
Narayana Superspecialty HospitalHowrah, West BengalDirections ↗
Netaji Subhas Chandra Bose Cancer HospitalKolkata, West BengalDirections ↗
Basavatarakam Indo American Cancer Hospital & Research InstituteHyderabadDirections ↗
Registry summary (technical)
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untreated, locally advanced or metastatic NSCLC with KRAS G12C mutation
Sponsor: Mirati Therapeutics Inc.
NCT06875310 on ClinicalTrials.gov
Last updated on the registry 13 Oct 2026 · read by us 20 Oct 2026